Last updated: September 8, 2026
PEGASYS, Roche’s peginterferon alfa-2a, moved from a blockbuster hepatitis C treatment to a declining specialty product after direct-acting antivirals replaced interferon-based therapy. Roche’s reported product sales fell from more than CHF 1 billion annually before the direct-acting antiviral transition to a low-revenue maintenance product by the early 2020s. Its hepatitis B indication remains clinically relevant, but that market is smaller and competes with long-term oral antivirals.
PEGASYS has no conventional generic-entry pathway because it is a biologic. Its 12-year U.S. reference-product exclusivity expired in 2014, while the principal composition and manufacturing patent barriers have largely expired or reached the end of their commercial relevance. No FDA-approved biosimilar to peginterferon alfa-2a has materially changed the U.S. market.
What is PEGASYS and who markets it?
PEGASYS is peginterferon alfa-2a, a long-acting recombinant interferon administered by subcutaneous injection. Roche developed and commercialized the product through its pharmaceutical organization, with Genentech involved in U.S. commercialization and regulatory operations.
| Attribute |
PEGASYS |
| Active ingredient |
Peginterferon alfa-2a |
| Product type |
Pegylated recombinant biologic |
| Reference sponsor |
Roche |
| U.S. regulatory application |
BLA 103964 |
| Main U.S. indications |
Chronic hepatitis C and chronic hepatitis B |
| Administration |
Subcutaneous injection |
| Original U.S. approval |
2002 |
| Hepatitis B approval |
2005 |
| Principal competitors |
PegIntron, Sovaldi, Harvoni, Epclusa, Mavyret, Vemlidy, Viread, Baraclude |
| Primary commercial decline driver |
Replacement of interferon-based HCV treatment by oral direct-acting antivirals |
The product combines interferon alfa-2a with a branched polyethylene glycol molecule. PEGylation extends systemic exposure and permits once-weekly dosing compared with conventional interferon regimens.
What FDA indications does PEGASYS have?
PEGASYS was approved for chronic hepatitis C in adults and, in combination with ribavirin, for selected pediatric and adult populations. It was later approved for chronic hepatitis B in adults with compensated liver disease and active viral replication.
The product’s commercial importance differed sharply by indication:
- Hepatitis C generated the majority of historical revenue.
- Hepatitis B treatment remained a smaller, longer-duration market.
- HCV treatment shifted rapidly to short-course oral regimens after 2013.
- HBV patients often remain on chronic nucleoside or nucleotide therapy, limiting interferon’s role.
The FDA labeling for PEGASYS includes significant safety restrictions associated with interferon therapy, including depression, cytopenias, autoimmune disease, hepatic decompensation, and fetal risk. Those safety and tolerability burdens became commercially important when oral HCV therapies offered higher cure rates with shorter treatment durations and fewer systemic adverse effects (U.S. Food and Drug Administration [FDA], 2021).
How did direct-acting antivirals affect PEGASYS sales?
Direct-acting antivirals caused a structural collapse in the HCV interferon market. Sofosbuvir-based regimens and later pangenotypic combinations displaced PEGASYS because they offered oral administration, substantially higher sustained virologic response rates, shorter treatment courses, and no requirement for interferon in most patients.
The market transition accelerated after:
- Sovaldi approval in 2013.
- Harvoni approval in 2014.
- Epclusa approval in 2016.
- Mavyret approval in 2017.
By 2015, PEGASYS was no longer a preferred treatment for most newly diagnosed HCV patients in the United States or major European markets. The product retained limited use in markets with restricted access to direct-acting antivirals, in select retreatment settings, and for some legacy treatment protocols.
HCV competitive transition
| Period |
HCV treatment economics |
PEGASYS market position |
| 2002-2012 |
Interferon and ribavirin were foundational therapies |
Core treatment platform |
| 2013-2014 |
First high-value oral direct-acting antivirals launched |
Rapid erosion begins |
| 2015-2017 |
Multiple oral combination regimens reach market |
Interferon becomes non-preferred |
| 2018 onward |
Pangenotypic oral regimens dominate |
Residual and access-constrained demand |
The competitive shift was not a normal loss of market share. It removed the principal treatment role for PEGASYS in HCV.
What is the financial trajectory of PEGASYS?
Roche’s product-sales disclosures show a steep decline after the launch of direct-acting antivirals. The company has periodically changed reporting categories and product-sales detail, so historical figures should be compared on a rounded basis.
| Period |
Approximate annual PEGASYS sales |
Commercial interpretation |
| 2012-2013 |
More than CHF 1 billion |
Mature blockbuster before full DAA substitution |
| 2014 |
Roughly CHF 1 billion |
DAA launches begin changing treatment mix |
| 2015 |
Approximately CHF 600-800 million |
Rapid HCV displacement |
| 2016 |
Approximately CHF 400-500 million |
Residual HCV and HBV demand |
| 2017 |
Approximately CHF 200-300 million |
Product becomes a declining specialty asset |
| 2018-2019 |
Approximately CHF 100-200 million |
HCV use largely residual |
| 2020-2023 |
Tens of millions of Swiss francs annually |
Maintenance-stage commercial product |
On a peak-to-trough basis, PEGASYS revenue declined by more than 95%. The decline reflected volume loss rather than a normal price erosion cycle. Roche’s revenue exposure became concentrated in:
- Chronic hepatitis B.
- Markets where oral HCV therapies were unavailable or unaffordable.
- Existing treatment protocols and limited specialist use.
- Small residual demand for interferon-based therapy.
Roche’s reported product sales should not be interpreted as current U.S. net sales. They reflect worldwide sales and may include channel, currency, and reporting effects. Even with those adjustments, the direction is clear: PEGASYS transitioned from a major revenue contributor to a low-growth, low-scale product.
When did PEGASYS lose U.S. exclusivity?
PEGASYS lost its principal U.S. biologic exclusivity protection in 2014, 12 years after the original 2002 BLA approval. The later hepatitis B approval did not restart the 12-year reference-product exclusivity period.
| Protection category |
Approximate timing |
Effect |
| Original BLA approval |
2002 |
U.S. market entry |
| Twelve-year reference-product exclusivity |
Through approximately 2014 |
Prevented biosimilar approval during the exclusivity period |
| Core PEGylation and composition patents |
Mid-2010s, varying by patent and adjustment |
Principal technical barriers expired or weakened |
| Later method and formulation claims |
Variable |
Potentially relevant only to specific uses or presentations |
| Current market position |
Post-exclusivity |
No broad blocking exclusivity comparable to the original launch period |
Patent expiration did not create a conventional generic wave because PEGASYS is a biologic and the market had already moved away from interferon-based HCV treatment.
What patents protect PEGASYS?
PEGASYS protection historically rested on several patent categories:
- PEG-interferon conjugate composition claims.
- Branched polyethylene glycol architecture.
- Interferon production and purification methods.
- Formulation and stability claims.
- Dosing and treatment-method claims.
- Manufacturing know-how and analytical controls.
The strongest commercial protection came from the composition and PEGylation technology, not from later method-of-use claims. Composition patents generally expired before the product reached the end of its economic life in HCV.
A precise patent-by-patent freedom-to-operate analysis requires review of national patent registers, terminal disclaimers, patent-term adjustments, pediatric extensions, and claim scope. The commercial conclusion is more direct: no publicly apparent U.S. patent barrier now provides PEGASYS with blockbuster-level exclusivity.
Are PEGASYS patents listed in the Orange Book?
PEGASYS is regulated as a biologic under a BLA, not as a conventional small-molecule drug under an NDA. The Orange Book is therefore not the principal U.S. patent reference for PEGASYS.
The relevant regulatory framework is:
- BLA 103964 for the reference biologic.
- The FDA Purple Book for biologic reference-product and biosimilar information.
- U.S. patent records for composition, formulation, manufacturing, and method claims.
- Federal biologics law governing biosimilar approval and interchangeability.
An ANDA applicant cannot use a traditional Paragraph IV certification to challenge PEGASYS in the same manner as an applicant for a small-molecule drug.
Have companies filed Paragraph IV challenges against PEGASYS?
No conventional Paragraph IV challenge is central to PEGASYS competition because PEGASYS is a biologic. A biosimilar applicant would use the Biologics Price Competition and Innovation Act pathway, generally involving a 351(k) application and the statutory patent-information exchange commonly called the patent dance.
No FDA-approved peginterferon alfa-2a biosimilar has created a material U.S. entry event comparable to a successful Paragraph IV generic launch. The absence of such a launch has not protected PEGASYS from commercial decline because therapeutic substitution by newer HCV medicines occurred first.
What is the biosimilar risk for PEGASYS?
The direct biosimilar risk is moderate in theory but low in practical commercial significance.
Regulatory risk
The 12-year U.S. exclusivity period has ended. A qualified sponsor could pursue a 351(k) application if it can establish biosimilarity using analytical, pharmacokinetic, immunogenicity, and clinical evidence.
Commercial risk
A biosimilar would face a small and shrinking market. HCV treatment guidelines favor oral direct-acting antivirals, while HBV prescribing is dominated by oral therapies such as tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir.
Manufacturing risk
PEGASYS is more difficult to reproduce than a conventional chemical drug because the product requires control of:
- Interferon protein identity and activity.
- PEG conjugation profile.
- Molecular-weight distribution.
- Aggregation and degradation.
- Host-cell and process impurities.
- Immunogenicity.
- Container-closure and refrigerated stability.
Those requirements create development costs without guaranteeing a commercially attractive market. Manufacturing complexity may deter biosimilar investment even after legal exclusivity has expired.
What formulation patents and manufacturing barriers remain?
PEGASYS commercial protection includes product-specific formulation know-how and manufacturing controls. Relevant barriers may include:
- Stability of the PEG-interferon conjugate.
- Control of aggregation during storage.
- Dose uniformity in prefilled syringes.
- Protein concentration and excipient selection.
- Cold-chain handling.
- Release testing and potency assays.
- Consistency of PEG substitution and conjugate distribution.
These barriers are more important to product quality and regulatory approval than to long-term exclusivity. Narrow formulation claims could still affect a specific follow-on product, but they do not recreate the original composition-patent moat.
What patent litigation and settlements affect PEGASYS?
PEGASYS has not generated a current U.S. litigation pattern comparable to major small-molecule patent disputes involving high-value oncology or immunology products. The principal legal risk moved from patent enforcement to regulatory and commercial obsolescence.
No major active settlement agreement is publicly associated with a current U.S. generic or biosimilar launch against PEGASYS. Historical disputes involving interferon, PEGylation, or hepatitis C intellectual property may affect the broader technology landscape, but they do not appear to preserve a significant current PEGASYS monopoly.
What licensing deals supported PEGASYS?
PEGASYS depended on licensed or internally controlled PEGylation and biologics technologies. Roche filings have disclosed third-party royalty and technology obligations across its product portfolio, although public reporting does not consistently provide product-level economics for PEGASYS.
The commercial significance of those arrangements declined with sales. At peak revenue, royalty-bearing technology could affect gross margin and licensing economics. At current revenue levels, manufacturing scale, supply commitments, regulatory maintenance, and distribution costs are more relevant than royalty leverage.
How does PEGASYS compare with PegIntron?
PegIntron, peginterferon alfa-2b, was the principal direct interferon competitor. The two products shared the same broad commercial problem: oral HCV therapies eliminated the need for interferon in most patients.
| Factor |
PEGASYS |
PegIntron |
| Interferon type |
Alfa-2a |
Alfa-2b |
| Sponsor history |
Roche |
Merck/Schering-Plough lineage |
| Main historical use |
HCV and HBV |
Primarily HCV |
| Dosing model |
Once weekly |
Once weekly |
| Current HCV relevance |
Low |
Low |
| Direct biosimilar pressure |
Limited |
Limited |
| Main competitive threat |
Oral DAAs |
Oral DAAs |
PEGASYS had an advantage in hepatitis B because of its approved HBV indication. That distinction did not prevent the loss of HCV revenue.
What generic launch scenarios exist for PEGASYS?
Three scenarios are commercially plausible:
Scenario 1: No U.S. biosimilar launch
This is the most likely commercial outcome. The market is too small relative to development and manufacturing costs, and physicians have better-supported oral alternatives for the principal indications.
Scenario 2: Limited biosimilar entry
A biosimilar could enter for institutional, government, or price-sensitive markets. The product would likely compete on price in HBV or in countries where direct-acting antivirals remain constrained.
Scenario 3: Regional follow-on competition
Non-U.S. jurisdictions may permit locally developed or non-reference peginterferon products under national regulatory pathways. Such products could pressure Roche in emerging markets without producing a large U.S. revenue shock.
What is the geographic coverage of PEGASYS?
PEGASYS historically had broad global registration, including the United States, Europe, Japan, and other markets. Its current commercial value is uneven:
- North America: HCV demand is largely displaced by oral DAAs.
- Western Europe: Similar substitution, with limited residual use.
- Japan: HCV treatment also shifted to oral agents, reducing interferon demand.
- Emerging markets: Access and reimbursement can preserve limited interferon use.
- HBV-endemic markets: Oral antivirals generally remain preferred, but peginterferon retains a defined clinical role in selected patients.
Global revenue therefore depends less on patent geography than on reimbursement, procurement policy, supply continuity, and local treatment guidelines.
How strong is the PEGASYS patent estate?
The PEGASYS patent estate is weak as a current revenue-defense mechanism but remains relevant for technical replication.
| Dimension |
Assessment |
| Original composition patents |
Largely expired or commercially exhausted |
| Regulatory exclusivity |
Expired in the United States |
| Formulation protection |
Potentially narrow and product-specific |
| Manufacturing know-how |
Meaningful technical barrier |
| Method-of-use protection |
Limited commercial leverage |
| Biosimilar exposure |
Legally possible, commercially limited |
| Litigation leverage |
Low relative to launch-period levels |
| Revenue durability |
Low |
| HBV franchise value |
Residual but clinically established |
Key Takeaways
- PEGASYS revenue declined by more than 95% from its pre-DAA peak.
- Oral direct-acting antivirals, not generic competition, caused the principal commercial collapse.
- U.S. biologic exclusivity expired approximately 12 years after the 2002 approval.
- PEGASYS is not subject to the conventional Orange Book Paragraph IV pathway.
- No FDA-approved peginterferon alfa-2a biosimilar has created a major U.S. market event.
- The strongest remaining barriers are manufacturing complexity, product characterization, and limited market economics.
- Hepatitis B preserves residual clinical demand, but oral antivirals constrain PEGASYS growth.
- Current PEGASYS revenue exposure is small relative to Roche’s broader pharmaceutical portfolio.
FAQs
Is PEGASYS still commercially available?
PEGASYS remains a regulated peginterferon alfa-2a product in certain markets, but availability, labeling, and supply can vary by country. Its commercial presence is substantially smaller than before the direct-acting antiviral era.
Can a generic company make PEGASYS?
A conventional generic company cannot use the standard ANDA pathway for PEGASYS. A follow-on sponsor would generally need a biologics pathway, such as a U.S. 351(k) biosimilar application, or a jurisdiction-specific biologic approval route.
Does PEGASYS have pediatric exclusivity?
Any pediatric exclusivity or extension must be confirmed against the product’s historical FDA regulatory record and patent-term calculations. It would not restore the expired 12-year biologic exclusivity period.
Is PEGASYS used for hepatitis B today?
Yes, peginterferon alfa-2a can remain an option for selected chronic hepatitis B patients. Oral nucleoside and nucleotide analogs are more common for long-term viral suppression.
Could PEGASYS sales recover?
A broad recovery is unlikely because the HCV market has structurally shifted to oral direct-acting antivirals. A sales increase would require a change in treatment guidelines, supply conditions, or access economics rather than ordinary market expansion.
References
-
Hoffmann-La Roche Ltd. (2013-2023). Annual report. Basel, Switzerland: Roche.
-
U.S. Food and Drug Administration. (2021). PEGASYS (peginterferon alfa-2a) prescribing information. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Silver Spring, MD: FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA.
-
American Association for the Study of Liver Diseases and Infectious Diseases Society of America. (2023). HCV guidance: Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org
-
Terrault, N. A., Lok, A. S. F., McMahon, B. J., et al. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B. Hepatology, 67(4), 1560-1599.
